location:Home >News > Biological News

Biological News

Posted by star on 2019-12-02 16:56:21 Hits:110
<<  Back
Tarumoto, scientist from Cold Spring Harbor Laboratory found that AML cells are uniquely sensitive to genetic or chemical inhibition of Salt-Inducible Kinase 3 in vitroand in vivo and A SIK inhibitor YKL-05-099 suppresses MEF2C function and AML in vivo. This study has been published on Blood in this November.
Lineage-defining transcription factors (TFs) are compelling targets for leukemia therapy, yet they are among the most challenging proteins to modulate directly with small molecules. 
Tarumotos team previously used CRISPR screening to identify a Salt-Inducible Kinase 3 (SIK3) requirement for the growth of acute myeloid leukemia (AML) cell lines that overexpress the lineage TF MEF2C. In this context, SIK3 maintains MEF2C function by directly phosphorylating histone deacetylase 4 (HDAC4), a repressive cofactor of MEF2C. 
Here, they evaluated whether inhibition of SIK3 with the tool compound YKL-05-099 can suppress MEF2C function and attenuate disease progression in animal models of AML. Genetic targeting of SIK3 or MEF2C selectively suppressed the growth of transformed hematopoietic cells under in vitroand in vivoconditions. Similar phenotypes were obtained when exposing cells to YKL-05-099, which caused cell cycle arrest and apoptosis in MEF2C-expressing AML cell lines. An epigenomic analysis revealed that YKL-05-099 rapidly suppressed MEF2C function by altering the phosphorylation state and nuclear localization of HDAC4. Using a gatekeeper allele of SIK3, we found that the anti-proliferative effects of YKL-05-099 occurred through on-target inhibition of SIK3 kinase activity. 
Based on these findings, they treated two different mouse models of MLL-AF9 AML with YKL-05-099, which attenuated disease progression in vivoand extended animal survival at well-tolerated doses. These findings validate SIK3 as a therapeutic target in MEF2C-addicted AML and provide a rationale for developing drug-like inhibitors of SIK3 for definitive pre-clinical investigation and for studies in human patients.
Abebio News
Biological News
Wuhan Abebio Science Co.,Ltd
Room 708, Building 15, Hi-tech Bio-Agri, No.888 Gaoxin Avenue, East Lake High-tech Development Zone, Wuhan city, China
Email: abebio@abebio.com